Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?
- 2 June 2009
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 150 (11) , 803-808
Abstract
Some diabetes guidelines set low glycemic control goals for patients with type 2 diabetes mellitus (such as a hemoglobin A(1c) level as low as 6.5% to 7.0%) to avoid or delay complications. Our review and critique of recent large randomized trials in patients with type 2 diabetes suggest that tight glycemic control burdens patients with complex treatment programs, hypoglycemia, weight gain, and costs and offers uncertain benefits in return. We believe clinicians should prioritize supporting well-being and healthy lifestyles, preventive care, and cardiovascular risk reduction in these patients. Glycemic control efforts should individualize hemoglobin A(1c) targets so that those targets and the actions necessary to achieve them reflect patients' personal and clinical context and their informed values and preferences.Keywords
This publication has 19 references indexed in Scilit:
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approachesBMC Research Notes, 2009
- The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetesPatient Education and Counseling, 2008
- Cardiovascular Outcomes in Trials of Oral Diabetes MedicationsArchives of internal medicine (1960), 2008
- Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trialBMJ, 2008
- Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes MellitusAnnals of Internal Medicine, 2007
- Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trialBMJ, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- MULTIFACTORIAL INTERVENTION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETESJournal of Cardiopulmonary Rehabilitation, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998